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Epithelial ovarian cancer has the highest mortality of the gynecological malignancies. High
grade serous epithelial ovarian cancer (SEOC) is the most common subtype, with the major-
ity of women presenting with advanced disease where 5-year survival is around 25%.
Platinum-based chemotherapy in combination with paclitaxel remains the most effective
treatment despite platinum therapies being introduced almost 40 years ago. Advances in
molecular medicine are underpinning new strategies for the treatment of cancer. Major
advances have been made by international initiatives to sequence cancer genomes. For
SEOC, with the exception ofTP53 that is mutated in virtually 100% of these tumors, there
is no other gene mutated at high frequency. There is extensive copy number variation,
as well as changes in methylation patterns that will influence gene expression. To date,
the role of histones and their post-translational modifications in ovarian cancer is a rela-
tively understudied field. Post-translational histone modifications play major roles in gene
expression as they direct the configuration of chromatin and so access by transcription
factors. Histone modifications include methylation, acetylation, and monoubiquitination,
with involvement of enzymes including histone methyltransferases, histone acetyltrans-
ferases/deacetylases, and ubiquitin ligases/deubiquitinases, respectively. Complexes such
as the Polycomb repressive complex also play roles in the control of histone modifica-
tions and more recently roles for long non-coding RNA and microRNAs are emerging.
Epigenomic-based therapies targeting histone modifications are being developed and offer
new approaches for the treatment of ovarian cancer. Here, we discuss histone modifica-
tions and their aberrant regulation in malignancy and specifically in ovarian cancer. We
review current and upcoming histone-based therapies that have the potential to inform
and improve treatment strategies for women with ovarian cancer.
Keywords: histone, ovarian cancer, splicing, lncRNA, polycomb repressive complex, histone deacetylase inhibitors,
deubiquitinases, histone methyltransferases
INTRODUCTION
Epithelial ovarian cancer has the highest mortality of all of the
gynecological malignancies, with high grade serous epithelial ovar-
ian cancer (SEOC) the most common subtype. Due to general
or non-descript symptoms of early stage disease, the majority of
women initially present with advanced malignancy (Stage III or
IV) where 5-year survival can be as low as 25% (1, 2). Standard
of care is surgical debulking followed by combinations of platin-
based drugs such as carboplatin with paclitaxel [reviewed in Ref.
(3)]. Cisplatin was first approved by the Food and Drug Admin-
istration (FDA) for the treatment of ovarian cancer in 1978 (4),
while paclitaxel was approved in 1992 (5). Some evidence exists
to support the success of neoadjuvant chemotherapy in women
who present with advanced, unresectable primary ovarian cancer,
followed by interval debulking; however, data also exist suggesting
there is little or no benefit to this approach (6, 7). Most women
respond to standard of care chemotherapeutic drugs initially; but
the majority relapse within 2 years, ultimately developing broad
chemoresistance (8, 9).
Additional factors complicating the success of current treat-
ment strategies for SEOC is lack of a clear understanding of the
true site and cells of origin of this malignancy, with evidence
mounting that SEOC may in fact arise in the secretory fimbr-
ial cells of the fallopian tube (10, 11). Molecular heterogeneity
of ovarian cancer also poses challenges, with distinct molecu-
lar subtypes based on gene expression identified within identical
histopathological groupings such as SEOC (12). Knowledge of
post-translational histone modifications associated with cancer,
including ovarian cancer, is emerging. This review discusses his-
tones and their post-translational modifications (PTMs) as key
regulators of gene expression and DNA repair with relevance for
the treatment of ovarian cancer.
GENETICS AND GENOMICS OF SEOC, INFORMING NEW
THERAPIES
While advances in genetics have not fully addressed the chal-
lenges of treating ovarian cancer, elucidation of the mutational
SEOC landscape is informing the development of therapies tar-
geting DNA damage signaling pathways. Extensive international
efforts channeled into sequencing a large cohort of sporadic
SEOC through The Cancer Genome Atlas (TCGA) project has
been revealing. With the exception of TP53 that is mutated in
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almost 100% of these cancers, there is a relatively low frequency
of mutations (approximately 2–6%) in genes including BRCA1,
BRCA2, CSMD3, NF1, CDK12, FAT3, GABRA6, and RB1, that
might otherwise have been more directive for therapeutic tar-
geting (13). Determining the role of multiple gene mutations in
relation to the activation of cancer-associated signaling pathways
for individual tumors will however be of value for guiding targeted
therapies. The development of strategies to target mutant p53 pro-
teins will clearly have major relevance to SEOC (14). Furthermore,
large cohort studies of primary SEOC and SEOC cell line mod-
els have revealed extensive copy number variations that would
function as a major driver of aberrant gene expression (13, 15).
Creating great excitement in this field is the introduction of
a new class of drugs known as [poly (ADP-ribose) polymerase,
PARP] inhibitors, including drugs such as Olaparib® (AZD2281,
AstraZeneca), Rucaparib® (AG 014699, Clovis), and Veliparib®
(ABT-888, Abbot) (16, 17). PARP1 is important in the cellular
response to DNA damage, binding to single and double-strand
breaks where it mediates recruitment of factors activated in the
DNA damage response such as the serine/threonine protein kinase
Ataxia telangiectasia mutated (ATM) (18). In cells lacking func-
tional homologous recombination pathways, e.g., with mutation,
silencing, or other functional dysregulation of proteins involved in
DNA repair such as BRCA1 and BRCA2, PARP1 inhibition leads to
persistent double-strand breaks and cell death. This is particularly
relevant to SEOC where aberrations in DNA damage pathways are
well recognized as major driver of these tumors. The frequency of
germline BRCA1 and BRCA2 mutation in familial ovarian cancer
is around 17% (19, 20). While encouraging, not all women with
SEOC respond to PARP1 inhibition, and some that do will develop
resistance. Key molecular drivers of PARP1 sensitivity and resis-
tance are beginning to be elucidated (21–23) and trials of PARP1
inhibitors have shown promise (24). It is interesting to speculate
that manipulation of factors involved in chromatin accessibility
may have the potential to increase the success of PARP1 inhibitors
that are undoubtedly an exciting new therapeutic option for SEOC.
EPIGENOMICS AND SEOC, UNLOCKING NEW
OPPORTUNITIES FOR THERAPY
Aberrant DNA methylation and microRNA (miRNA) expression
have also been identified in SEOC (25,26). DNA methylation refers
to the addition of a methyl group to the cytosine-5 position of a
CpG dinucleotide that is controlled by DNA methyltransferases.
There are well described cases of gene regulation in ovarian cancer
relying on hyper- or hypomethylation, including down-regulation
of both BRCA1 and the PTEN tumor suppressors by promoter
hypermethylation (27, 28). Of note, the cell surface marker CD133
that is part of a panel used to define ovarian cancer-initiating
cells has been shown to be regulated by both histone modifi-
cation and promoter methylation (29). Other cancer-associated
genes with increased expression in ovarian cancer due to pro-
moter hypomethylation include TUBB3 and HOXA10 (30, 31).
Epigenetic silencing of genes has been linked to the develop-
ment of platin-based resistance in ovarian cancer, including DNA
hypermethylation at CpG sites of MLH1, ARMCX2, COL1A1,
MDK, and MEST gene promoters (26, 32). Treatment of cis-
platin resistant human ovarian cancer cell line xenografts with the
demethylating agent 5-aza-2′-deoxycytidine resensitized tumors
to platin-based therapy, likely through re-expression of MLH1
associated with a decrease in MLH1 promoter hypermethylation
(33). While unlikely to be efficacious as monotherapy, the value of
demethylating agents for the treatment of ovarian cancer may be
in combinatorial treatments with more conventionally used DNA
damaging agents such as the platin-drugs or other epigenomic-
based therapies. Interactions between histone modifications and
DNA methylation that together influence gene expression have
been reported (34). A number of reviews addressing the topic
of DNA methylation in ovarian cancer, including discussion of
clinical trials of demethylating agents, are available (25, 35, 36).
Elucidation of the role of post-translational histone modifica-
tions and parallel development of therapeutic strategies targeting
them is gaining momentum in many tumor streams; however,
this area of epigenomics is to date relatively understudied in ovar-
ian cancer, although examples of this form of gene regulation
are emerging. Targeting histone modifications has the potential
to be of particular relevance to the treatment of SEOC given
that these strategies embrace a whole genome approach, and so
have the potential to overcome issues created by focusing on infre-
quently mutated genes. Furthermore, many histone modifications
have been implicated in the DNA damage response given their
fine control of chromatin configuration that determines access
by transcription factors and DNA repair proteins (37). SEOC is
undoubtedly a tumor driven by aberrant DNA damage signaling,
therefore the potential exists to improve the way this pathway is
targeted with current therapies by a greater understanding of the
chromatin landscape. It has recently been stated that we stand at
the “tipping point ” for epigenetic based therapies for the treatment
of cancer (38). The strategies being developed have large potential
for the treatment of ovarian cancer.
MODIFYING CORE HISTONES
POST-TRANSLATIONAL HISTONE MODIFICATIONS
Histones are small basic proteins of around 14 kDa that contain
a high percentage of positively charged amino acids (39). They
are the most abundant proteins bound to DNA in eukaryotic cells
and predominantly function to regulate gene expression and DNA
packaging around nucleosomes, the functional units of chromatin.
Nucleosomes are comprised of a histone octamer with two copies
each of the core histone proteins H2A, H2B, H3, and H4 wrapped
around by approximately 147 bp of DNA (39). Within this struc-
ture, H3:H4 exists as a tetramer and there are two H2A:H2B dimers
(40). The histone linker H1 binds nucleosomes together thereby
participating in a higher order compaction of chromatin (41).
NH2-terminal histone tails protrude from the core octamer struc-
ture, with residues located in these tails subject to a large number
of dynamic and reversible PTMs that include, but are not limited
to, methylation, acetylation, phosphorylation, ubiquitination, and
SUMOylation (42).
Post-translational modifications of core histone proteins reg-
ulate gene transcription, replication, and DNA repair processes
by influencing chromatin configuration and providing impor-
tant platforms or docking sites for the recruitment of proteins
and enzyme complexes such as methyltransferases and acetylases
required for chromatin modeling. New terminology has recently
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entered this field describing chromatin “writers” that lay down
histone modifications, chromatin “erasers” that remove them, and
chromatin “readers” that are involved in interpretation of signals
that may influence subsequent changes (40). Histone H3 lysine
4 di- and tri-methylation (H3K4me2 and H3K4me3), as well as
histone H3 lysine 79 methylation (H3K79me), histone H3 lysine
36 (H3K36me), histone acetylation and monoubiquitination of
histone H2B at lysine 120 (H2Bub1) have been linked to “open”
chromatin and active transcription. Other modifications, includ-
ing methylation of histone H3 lysine 9 (H3K9me), histone H3
lysine 27 (H3K27me), and histone H4 lysine 20 (H4K20me) are
associated with “closed” chromatin and transcriptional repression
(42, 43). Suppression of H3K27me3 in cell lines overexpressing the
dominant negative mutant H3-K27R led to re-expression of the
RASSF1 tumor suppressor and resensitization of ovarian cancer
cells to cisplatin, likely due to a more relaxed and open chromatin
configuration (44). Methylation is controlled in a reversible fash-
ion by methyltransferases and demethyltransferases, often asso-
ciating in complexes, whilst monoubiquitination is dynamically
controlled by ubiquitin ligases such as the RING finger proteins
RNF20 and RNF40 (45, 46) and deubiquitinases (DUBs), again
often in complex structures.
Histone acetylation is generally associated with an open chro-
matin structure that facilitates transcription, controlled in a
dynamic fashion by histone acetyltransferases (HATs) and histone
deacetyltransferases (HDACs) (47). Acetylation acts to neutral-
ize the positive charge of lysine residues located on histone tails,
resulting in disruption of nucleosomal structure and promoting
unfolding of local DNA making it more accessible by transcrip-
tion machinery. HDACs remove acetyl residues and consequently
are associated with gene repression. In many cancers including
ovarian, aberrant HDAC pathways are believed to promote cancer
growth and metastasis (48–50). Histone tail residues can provide
platforms for multiple enzyme writers, such as lysine 120 of his-
tone H2B that in addition to being monoubiquitinated, can also be
acetylated (H2BK120ac). It is thought in this case that H2BK120ac
precedes H2Bub1 in a temporal fashion, suggesting that it may be
an early mark of poised or active chromatin functioning as a dual
switch to keep nucleosomes “hot” for rounds of induction and
transcriptional elongation (51).
Histone deacetyltransferases that are aberrantly expressed in
cancer include sirtuins of which there are seven family members.
Sirtuins are mammalian homologs of the yeast silent informa-
tion regulator (Sir2), that as well as functioning as HDACs can
act as deacetylases for non-histone proteins such as p53 (52).
SIRT1 is a nicotinamide adenine dinucleotide (NAD+) – depen-
dent lysine deacetylase and a class III HDAC. SIRT1 expression
was reported to be higher in malignant EOC compared to benign,
and expression was seen more commonly in SEOC relative to
mucinous tumors (53). This same study reported higher levels
of SIRT1 in a subset of malignant SEOC that correlated with
increased overall survival. Of note, BRCA1-associated breast can-
cers have been reported to have lower levels of SIRT1 relative
to BRCA1 wild-type (54). To date, levels of SIRT1 in BRCA1-
associated EOCs have not been assessed. SIRT1 is also associated
with acquired drug resistance, influencing the tumor microenvi-
ronment, functioning in DNA repair and promoting cancer stem
cell survival (55). For all these reasons, SIRT1 is being considered as
a possible target to overcome drug resistance seen in many malig-
nancies and may have relevance to future treatment strategies for
SEOC.
There is emerging evidence to support the theory that sub-
populations of cells exist in SEOC that are of a stem cell-like
nature, demonstrate resistance to chemotherapy and are respon-
sible for the development of chemoresistance in women with
ovarian cancer (56–58). This is supported by a recent study
demonstrating that the bivalent chromatin mark seen in embry-
onic stem cells and required for silencing of developmental genes,
H3K27me3/H3K4me3, is found in SEOC at the transcription
start sites of silenced genes (59). H3K27 methylation is written
by the methyltransferase Enhancer of Zeste Homolog 2 (EZH2)
that forms the catalytic unit of Polycomb repressive complex 2
(PRC2). EZH2 is overexpressed in SEOC, as well as in cancer-
associated stromal cells (60). H3K27me has also been associated
with chemoresistance in ovarian cancer (59). Histone PTMs play
a major role in maintenance of an undifferentiated stem cell
phenotype (61, 62).
Studies of histone PTMs in primary tumors support discoveries
in cancer cell line models of complex histone modifications and
furthermore, have been shown to correlate with tumor stage and
prognosis. Loss of global H3K27me3 has been shown in ovarian, as
well as breast and pancreatic cancers, correlating with shorter over-
all survival (63). Loss of global levels of H2Bub1 has been reported
in advanced breast tumors, as well as colon, lung, parathyroid, and
ovarian cancers (64–67).
CROSS-TALK BETWEEN HISTONE MODIFICATIONS
Histone cross-talk is defined as the influence that one or more
post-translationally modified histones have on the writing, eras-
ing, and reading of other histone PTMs. The language of histones
is both complex and wide spread, influencing processes involved
in development, stem cell differentiation, transcription, replica-
tion, and DNA repair with a major role in the regulation of gene
expression (68, 69). Examples of histone cross-talk include the
recruitment of the methyltransferase complex COMPASS (com-
plex of proteins associated with Set1) by H2Bub1 that is involved
in the methylation of lysine 4 on histone H3 (70–73) (Figure 1).
This cross-talk also has implications for DNA damage signaling as
methylated H3K4 recruits the DNA damage-associated chromatin
remodeling factor SNF2H leading to recruitment of DNA repair
proteins RAD51 and BRCA1 (74, 75). The DOT1L methyltrans-
ferase has been shown to methylate H3K79 after its expression
was first stimulated by increased H2Bub1 (76). Complex patterns
of cross-talk and their influence on gene expression and cellular
processes are only just beginning to be elucidated. This will be an
area of considerable focus in the future given the importance of
understanding how therapies targeting one histone modification
may in fact be influencing another.
DIFFERENTIAL HISTONE SPLICING
The study of histone splice variants in ovarian cancer is still in
its infancy, with few studies published to date, although evidence
suggests roles in tumor progression (77). Slight structural changes
to the core histone octamer as the result of incorporation of
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FIGURE 1 | Postulated patterns of histone cross-talk in malignancy.
(A) Lysine 120 of histone H2B is acetylated by histone acetyltransferases
(HATs), acting as a precursor for histone H2B monoubiquitination at the same
amino acid residue. (B) Lysine 120 of histone H2B becomes deacetylated via
histone deacetylases (HDACs), allowing for the E3 ubiquitin ligase complex of
RNF20/RN40, in association with the PAF1 transcriptional regulatory complex
(PAFC) to facilitate monoubiquitination of lysine 120 (H2Bub1). (C) SET1 is
recruited to the site of H2Bub1 where it interacts with COMPASS (complex of
proteins associated with Set1) to facilitate the active mark of methylated
histone 3 at lysine 4 (H3K4me). (D) H2Bub1 can recruit and activate the
DOT1L methyltransferase, responsible for the active chromatin mark of
methylated histone H3 at lysine 79 (H3K79me).
differentially spliced histones can alter the overall structure of the
nucleosome, changing the way in which DNA wraps around it and
influencing nucleosome dynamics (78). These non-canonical vari-
ants can influence the function of chromatin domains and lead to
differences in nucleosome stability causing aberrant transcription
and DNA repair (79). Roles for histone splicing are just beginning
to be elucidated in ovarian cancer. A link between alternative his-
tone splicing of a group of H2A-type histone variants, referred to
as macroH2As (macroH2A1.1, macroH2A1.2, and macroH2A2),
and proliferation has been reported in a number of cancers, includ-
ing ovarian (80). The RNA binding protein QKI (Quaking) was
shown to regulate alternative pre-mRNA splicing of macroH2A1.
Interestingly, macroH2A1.1-mediated suppression of prolifera-
tion occurs, at least in part, through the reduction of PARP1
protein levels. Given the interest in PARP1 inhibition for therapy,
this area requires further attention.
Another histone variant identified to be down-regulated in
ovarian cancer is histone variant H2A.Z, loss of which resulted
in tumor progression (81). H2A.Z is a conserved variant of his-
tone H2A, and has recently been shown to regulate a variety of
targets including the glucocorticoid receptor (82), estrogen recep-
tor (83), and p53 (84). The ovarian cancer cell lines A2780 and
OVCAR3 were shown to have lost H2A.Z from regulatory regions
of the urokinase receptor (u-PAR) leading to activation of this
receptor and suggesting a mechanism for upregulation of u-PAR
that is seen in a number of different malignancies (81, 85, 86).
Furthermore, expression of linker histone H1 splice variants has
been shown to discriminate ovarian adenocarcinomas from ade-
nomas, suggesting their value as potential epigenetic biomarkers
of ovarian cancer (87).
ROLE OF NON-CODING RNAs IN THE REGULATION OF
HISTONES
The surprising finding that at least 80% of the human genome is
transcribed has boosted an interest in understanding the role of
non-coding RNAs (lncRNAs) in biological processes and diseases.
The number of protein coding genes has remained relatively sta-
ble at approximately 21,000 during the last decade; however, the
number of lncRNAs has grown to 9000 small lncRNAs (<200 nt)
and 10,000–32,000 long lncRNAs (>200 nt) (88).
The role of miRNAs, a subset of small lncRNAs, in regulation of
post-transcriptional gene silencing has been well established; how-
ever, our understanding of their effects on biological networks is
still far from complete (88). Global deregulation of miRNAs has
been implicated in ovarian cancer, and miRNAs have been found
to target DICER, a key enzyme in miRNA processing, in breast
cancer (13, 89–92). Of note, DICER levels do not appear to be
altered in ovarian cancer (91). DNA methyltransferases such as
DNMT1 and DNMT3B, histone deacetylases such as HDAC2 and
HDAC4, and HATs such as KAT2B and KAT6A themselves are pre-
dicted to be targeted by dysregulated miRNAs in ovarian cancer
(miR-100, 140, 145, 21, 26a, and 93) according to miRTarBase, a
database of experimentally validated miRNA targets, influencing
the epigenome (93).
HOTAIR, EZH2, AND THE POLYCOMB REPRESSIVE COMPLEX
Non-coding RNAs are versatile, with roles ranging from chromatin
structure modification, X chromosome inactivation, scaffold func-
tion, miRNA decoys, nuclear import and export, RNA splicing,
and the regulation of gene expression (94–96). Recently, approx-
imately 20% of long intergenic lincRNAs, a subset of lncRNAs,
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FIGURE 2 | HOTAIR -directed epigenetic reprograming of the cancer
genome. (A) The long intergenic non-coding (linc) RNA HOTAIR recognizes
specific DNA sequences and targets chromatin-modifying complexes PRC2
and LSD1 to silence gene loci. The 5′ end of HOTAIR tethers the PRC2
complex to the target by binding to the non-coding RNA binding domain
(ncRBD) of the HMTase EZH2, catalyzing tri-methylation of H3K27. The 3′
end of HOTAIR facilitates demethylation of H3K4me2 by the lysine-specific
demethylase LSD1. Both H3K27me3 and lack of methylation at H3K4 are
repressive chromatin marks associated with gene silencing. (B) Expression
of HOTAIR results in silencing of >40-kb region spanning HOXD8–11 of the
HOXD locus. Aberrant HOTAIR expression in multiple cancers has been
shown to promote invasiveness.
have been found to be associated with PRC2 that functions
as a chromatin-modifying complex (97). HOTAIR (HOX tran-
script antisense intergenic RNA), an approximately 2.1 kb lin-
cRNA transcribed from the HOXC locus, is known to alter
chromatin configuration and promote cancer. In healthy cells,
HOTAIR functions to epigenetically silence approximately 40 kb
spanning HOXD8–HOXD11 of the HOXD region on chromo-
some 2 (98, 99). By working as a scaffold, HOTAIR tethers and
directs the PRC2 containing the H3K27 methylase EZH2, and
the lysine-specific demethylase 1 (LSD1) to silence targets by
catalyzing H3K27me3 and demethylating H3K4me2, depicted in
Figure 2 (100).
Over-expression of HOTAIR promotes metastasis of breast,
pancreatic, endometrial, colorectal, and other cancers (99, 101–
104). Conversely, silencing of HOTAIR impaired migration and
invasion of EOC cells in vitro, as well as inhibited tumor spread
in a mouse model of intraperitoneal metastasis, likely via met-
alloproteinases (MMP3 and matrix metalloproteinase-9, MMP9)
and epithelial-to-mesenchymal pathways (105). HOTAIR levels
were reported to be elevated in ovarian cancer relative to normal
ovary, and its expression was inversely correlated with the degree
of differentiation (101, 105). Elevated levels of HOTAIR correlated
with worse overall and disease free survival in women with EOC
and were also correlated with the presence of lymph node metas-
tasis (105). Furthermore, HOTAIR is expressed at a fivefold higher
level in cisplatin resistant A2780cisR cells compared to parental
A2780 cells, and its down-regulation restored cisplatin sensitivity
(106). Levels of HOTAIR have been reported to be fourfold higher
in colon and breast cancer stem cell-like cells (CD133+/CD44+)
compared to non-stem cell-like cells (CD133−/CD44−), and
its down-regulation reduced the number and size of colonies
assessed by anchorage-independent growth (107). HOTAIR was
also shown to induce epithelial-to-mesenchymal transition (EMT)
following TGF-β1 treatment in colon and breast cancer cell
lines (107).
Polycomb-group (PcG) proteins are involved in maintaining
the repression of genes in specific cells and subsequent cells
originating from them. These proteins are essential in lineage
commitment where they and their antagonists, Trithorax pro-
teins, selectively express and repress a subset of HOX genes
required to specify a particular cell type. Tumor suppressors
including p16Ink4a, p19Arf , and p15Ink4b are epigenetically silenced
due to abrogation of PcG proteins in cancer (108). Most PcG
proteins form multimeric complexes of either Polycomb repres-
sive complex 1 (PRC1) or 2 (PRC2). Mammalian PRC2 com-
plex comprises four core PcG proteins: EED, SUZ12, EZH1/2,
and RbAp46/48, with many other proteins interacting with this
core complex. EZH1 and EZH2 are histone methyltransferases
(HMTases) and form part of the PRC2 complex that initiates
gene silencing. As HMTases, gene silencing is enabled as both
EZH1 and EZH2 contain SET domains required to catalyze
di- or tri-methylation of H3K27 (H3K27me2 and H3K27me3)
and repress chromatin. The PRC1 complex binds to chromatin
bearing the H3K27me3 mark. PRC1 is composed of ubiqui-
tin ligases RING1A and RING1B together with BMI1, MEL18
(PCGF2), and NSPC1 (PCGF1), with RING proteins functioning
to monoubiquitinate histone H2A at lysine 119 (H2AK119ub1)
(108). Both PRC1 and PRC2 are required to maintain gene sup-
pression, and remain associated with condensed chromatin, even
in the absence of the initial trigger. Although PRC1 usually fol-
lows the activity of PRC2, there are some reports where PRC2
silenced genes do not contain the PRC1-mediated H2AK119ub1
mark (108).
The components of PRC2 are upregulated in many malig-
nancies such as melanoma, lymphoma, and breast cancers. High
expression of EZH2 is seen in ovarian cancer, correlating with
advanced stage and is a predictor of poor survival (109). Further-
more, higher levels of EZH2 have been seen in a subpopulation
of ovarian cancer cells with stem cell-like properties at relapse fol-
lowing platinum-based chemotherapy. Down-regulation of EZH2
in these stem cell-like populations in ovarian cancer cell mod-
els reduced anchorage-independent growth and tumor growth
in vivo (110). Furthermore, down-regulation of EZH2 was shown
to resensitize cisplatin resistant ovarian cancer cells to cisplatin
and decrease H3K27me3 levels (111). In line with this discovery,
down-regulation of EZH2 leads to re-expression of p21waf1/cip1,
subsequently promoting apoptosis (112).
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FIGURE 3 | Current and upcoming therapies for the targeting of
epigenetic modifiers in ovarian cancer. Tumor suppressor genes are
commonly silenced in ovarian cancer through epigenetic writers and erasers
(blue ovals). These proteins regulate a variety of modifications including DNA
methylation (DNMTs), histone methylation (EZH2), the removal of both
histone acetylation (HDACs), and histone monoubiquitination (DUBs). Various
inhibiting agents (red ovals) have been designed to stop the action of these
enzymes. DNA methyltransferases (DNMTs) silence tumor suppressor genes
(red line) by hypermethylation of CpG islands in gene promoters (yellow line).
Consequently, DNMT inhibitors (DNMTi) are currently being trialed in ovarian
cancer cell models with value in the reactivation of a tumor suppressive
phenotype. Deubiquitinating enzymes (DUBs) function to cleave ubiquitin
from their target proteins. Recent research has demonstrated H2Bub1 is lost
in ovarian cancer, implicating H2Bub1-specific DUBs. H2Bub1-associated
DUB inhibitors (DUBi) may be viable treatments for ovarian cancer. The
histone methyltransferase EZH2 is a member of the Polycomb repressive
complex 2 (PRC2). EZH2 functions to tri-methylate lysine 27 of histone H3
(H3K27), a repressive chromatin mark. Consequently, EZH2-inhibitors (EZH2i)
are currently being trialed to remove this repressive mark. Histone
deacetylase (HDACs) remove acetyl groups from specific histone residues.
HDAC inhibitors (HDACi) prevent this enzymatic function, facilitating gene
transcription.
The PRC2 complex proteins rely on association with molecules
that have DNA-binding abilities such as the lncRNAs HOTAIR
and Xist or the transcription factor JARID2 to direct it to its
target (108). A number of repressed or deleted miRNAs associated
with ovarian cancer, including miR-199a, miR-214, and miR-26a
(89, 90), are also predicted (miRTarBase)1 and/or reported to
directly target EZH2 suggesting a possible mechanism of its over-
expression (113, 114). Interestingly, the tumor suppressor BRCA1
negatively modulates PRC2 by interacting with EZH2 due to over-
lap in the BRCA1-binding region and HOTAIR binding domain
of EZH2 (115). HOTAIR reprograms luminal breast cancer cells
into an aggressive, basal-like state in the absence of functionally
wild-type BRCA1 (115). Although the dominant mechanism of
PRC2 function is via the H3K27me3 repressive mark on target
loci, multiple epigenetic mechanisms could also be involved in
PRC2-mediated gene silencing since EZH2 and EED are reported
to interact with DNMTs and HDACs (25). Unlike EZH1, which is
present in both dividing and differentiated cells, EZH2 expression
is specific to actively dividing cells (108), making it an attractive
therapeutic target for cancer.
1http://mirtarbase.mbc.nctu.edu.tw/
RISE OF EPIGENETIC THERAPIES TARGETING HISTONE
MODIFICATIONS
Knowledge of epigenetic modifications and the enzymes that reg-
ulate them underpin new options for the treatment of ovarian
cancer. Drugs specifically targeting DNA methylation will not
be discussed but we recommend a recent review addressing this
topic (116). In this section, we will examine the rapidly expanding
field of drugs targeting histone modifications and the enzymatic
machinery driving these changes with the view of application for
the treatment of ovarian cancer. Figure 3 depicts histone modify-
ing enzymes currently being targeted or in pre-clinical models for
ovarian cancer.
HISTONE DEACETYLASE INHIBITORS
Histone deacetyltransferase inhibitors have been demonstrated
to decrease cancer cell growth, induce apoptosis and promote
cell differentiation (117). Currently, there exists a wide variety
of compounds that can function as HDAC inhibitors including;
organic hydroxamic acids, short-chain fatty acids, benzamides,
cyclic tetrapeptides, and sulfonamides (118). Many different type
of agents derived from these fundamental families are currently
going through clinical trials. Of the current HDAC inhibitors, three
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have been tested in ovarian cancer; suberoylanilide hydroxamic
acid (SAHA), valproic acid (VPA), and Romidepsin, either as
standalone treatments or in conjunction with DNA damaging
agents such as cisplatin. Although this section will focus on FDA
approved HDAC inhibitors, other HDAC inhibitors have also
recently shown for the potential treatment of ovarian cancer. The
HDAC inhibitor M344, which is specific for HDAC6 and to a lesser
extent HDAC1, has been shown to promote growth inhibition, cell
cycle arrest, and apoptosis, as well as inhibit BRCA1 expression in
ovarian cancer cell lines (119, 120). The HDAC inhibitor Tricho-
statin A (TSA), which specifically inhibits class I and II mammalian
HDAC families, has been shown to increase p73 expression and
promote Bax-dependent apoptosis in cisplatin resistant ovarian
cancer cells (121).
SAHA (Vorinostat®)
Suberoylanilide hydroxamic acid has showed promising results in
a number of in vitro models of ovarian cancer. Early research
demonstrated that SAHA was capable of promoting cell cycle
arrest, apoptosis, and caspase 3 activation, as well as decrease cell
viability in ovarian cancer cell lines and isolated primary cancer
cells (122–124). More recent studies have demonstrated that SAHA
works effectively in conjunction with paclitaxel in ovarian cancer
cell lines (125), while a SAHA–decitabine combination inhibited
ovarian cancer cell growth in both in vitro and in xenograft models,
in addition to increasing the expression of imprinted tumor sup-
pressor genes, increasing apoptosis, cell cycle arrest, and autophagy
(126). Further work has shown SAHA to be effective in combina-
tion with cisplatin in platinum resistant ovarian cancer cells (127,
128); however, the mechanism of this effectiveness is still poorly
defined. Research has linked SAHA treatment to growth arrest,
apoptosis and differentiation in a wide range of cancers. The anti-
proliferative effect of SAHA has been suggested to be a result of
the accumulation of acetylated proteins, including; BCL6, p53,
Hsp90, and the core histones (129). Currently, Vorinostat has been
through phase I and II clinical trials for ovarian cancer. Phase II
trials in women with recurrent platinum-refractory ovarian can-
cers showed little benefit when this drug was used as a single agent,
although the drug was well tolerated (130). Vorinostat was FDA
approved in 2006 for the treatment of Cutaneous T-cell lymphoma
(CTCL).
Valproic acid (Valproate®)
Another HDAC inhibitor showing promise is the short-chain fatty
acid drug VPA. Valproate has the advantage of already being a well
establish FDA approved drug, used clinically as an anticonvulsant.
VPA acts to directly inhibit HDAC activity; however, the specific
details of how it exerts its effects are still unclear. Early research
demonstrated that VPA promoted cell cycle arrest and apoptosis
in ovarian cancer cell lines (122). VPA was also demonstrated to
sensitize ovarian cancer cell lines to cisplatin treatment and to
resensitize cisplatin resistant cells to treatment (131). More recent
research showed that VPA was effective at treating a mouse sub-
cutaneous xenograft model of ovarian cancer, as well as ovarian
cancer cell lines (132). This same study demonstrated that VPA
treatment resulted in an increase in E-cadherin expression, while
decreasing MMP9 and vascular endothelial growth factor (VEGF).
Similar to SAHA, VPA has been shown to act as an effective treat-
ment against ovarian cancer cells by itself and in combination with
other drugs. Combination treatments of ovarian cancer cell line
models with VPA and the Aurora Kinase inhibitor VE465 showed
increased apoptosis compared to VE465 alone (133). Monti and
colleagues offer an extensive review of VPA mechanisms (134).
Romidepsin (FK228, Istodax®)
Romidepsin is a class I HDAC inhibitor, which received FDA
approval in 2009 for the treatment of CTCL. In a biological system
Romidepsin functions as a pro-drug whereby its reduction results
in the release of a thiol, which blocks the activity of Zn-dependent
histone deacetylase through its interactions with the zinc atom
present in the deacetylase’s binding domain (135). A study has
demonstrated that Romidepsin inhibited cell viability and induced
apoptosis in ovarian cancer cell lines (136). More recent work by
the same group demonstrated that Romidepsin worked effectively
in combination with cisplatin increasing cell apoptosis in in vitro
and in vivo models (137). Romidepsin is currently in phase 2 trials
for ovarian cancer2 (NCT00085527).
DEUBIQUITINASES – TARGETING MONOUBIQUITINATED HISTONE H2B
(H2BUB1)
Ubiquitin is traditionally thought of in the context of polyubiq-
uitination that leads to protein degradation via the ubiquitin–
proteasome system; however, monoubiquitination of histones
H2A and H2B are clear instances of alternative roles for ubiq-
uitin in transcription and DNA repair (45, 46, 138). DUBs are
proteases that cleave ubiquitin from target proteins, including core
histone proteins, and are recognized as important regulators of the
ubiquitin–proteasome system. Given that DUBs occur upstream
of the proteasome, they have the potential to show greater speci-
ficity and less toxicity compared to FDA approved proteasome
inhibitors such as Velcade® (bortezomib) or Kyprolis® (carfil-
zomib). For these reasons, extensive efforts are currently being
focused on DUBs as drug targets (139, 140). Currently, no specific
DUB inhibitor has entered clinical trials; however, DUB inhibitors
have shown promise in pre-clinical models, including P0591, an
inhibitor of USP7, that has amongst its substrates H2Bub1 and
the p53 regulator HDM2 (141). In studies of multiple myeloma,
P5091 was demonstrated to induce apoptosis in both bortezomib
refractory multiple myeloma cells and animal tumor models (141).
Further, there is considerable interest in the H2Bub1-targeting
DUB USP22 given its membership of an 11-gene panel termed
the “Death-from-Cancer” signature that predicts rapid disease
recurrence, distal metastasis, and poor response to therapy (142).
HISTONE METHYLTRANSFERASES – TARGETING EZH2
Like DNMTs, HMTases such as EZH2 can be targeted for ther-
apy. 3-Deazaneplanocin A (DZNep) was the first indirect inhibitor
of EZH2, leading to decreased global levels of H3K27me3 and
restoration of expression of genes involved in growth inhibition
or apoptosis (143). It was subsequently discovered that DZNep
also inhibited other HMTases (60, 143, 144). Specific inhibitors of
2http://clinicaltrials.gov/ct2/crawl/42
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EZH2 have since been developed including GSK126, EPZ005687,
and EI1 (60, 145–147). Recently, a peptide-based inhibitor, SAH-
EZH2, was developed to target the PRC2 by disrupting EZH2/EED
interactions (148).
Results of preliminary studies of EZH2-inhibitors in com-
bination with other drugs have been encouraging. DZNep was
shown to enhance the anti-proliferative effects of Gemcitabine
in pancreatic cancer cells (149). The combination of both DNA
demethylating agents (5-aza-2′-deoxycytidine) and DZNep tar-
geting histone methylation has shown promise in cell line models
of leukemia (150). A report on the use of DZNep treatment of the
ovarian cancer cell line A2780 showed reduction in proliferation,
an increase in apoptosis, inhibition of migration, and upregula-
tion of E-cadherin expression (151). It remains to be seen whether
these therapeutic strategies may be of value for the treatment of
ovarian cancer.
CONCLUDING REMARKS
Targeting of histone modifications and the enzymes regulating
them in the ovarian cancer epigenome represents, to date essen-
tially an unmet opportunity. With further focus on this field, it is
probable that within the next decade new drugs targeting HDACs,
HTMases, and DUBs will emerge as the next generation of cancer
therapeutics. Whether these drugs will be most efficacious as sin-
gle agents, or in combinatorial approaches with more traditional
DNA damage-based chemotherapeutics, or with other perhaps
yet to be developed molecular based targeted drugs remains to be
determined. It is clear that complex networks of histone cross-talk
will need to be understood and markers of histone dysregulation
will need to be identified to ensure that patients receive maxi-
mal benefit from these therapies (152). In summary, the field of
epigenomic-based histone therapies promises to offer a new gen-
eration of cancer therapeutics giving fresh hope for the treatment
of women with ovarian cancer.
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